Among the earliest and most influential, Besse et al. introduced second‐generation DEXs by stimulating Mo‐DCs from non‐small cell lung cancer (NSCLC) patients with IFN‐γ.[86] This maturation process induced the secretion of EVs enriched in immunologically active proteins, including MHC class I, CD86, and BAG6. This evidence concerns the gene CD86 and lung cancer.